HOUSE-WELLNESS-FOODS
Vietnam is a nation that has seen its share of turmoil and suffering over the past century, and emerged from it with strength, enthusiasm, dedicated to progress and self-sufficiency. Over the past 50 years its participation on the global stage has steadily risen, with ever-increased attention to commerce, health, and education.
As much as 35% of Vietnam’s aquacultural activity is built around river farming of the juvenile striped catfish [Pangasianodon hypophthalmus ] , making it the world’s largest producer of this nutritious staple, not only for its own consumption but for export to China, Europe, and elsewhere.
Vietnam’s story is one of many that expose the dual edge of farming to emerging populations. It’s been the keystone of civilization’s advancement since the dawn of humankind, but where resources are limited and need is great, farming’s potential hazards become viciously clear. Overstocked waters turn hazardous to human life due to excessive waste production and a rise in bacteria, parasites, fungi, and viruses. Overstocked waters produce fish that are increasingly malnourished, enervated, injured, and unable to reproduce.
The reflex response to this blight has been the use of antibiotics to keep weakened fish populations alive. Apart from expense, before long, disease-inducing agents mutate to resist the antibiotic, which, in turn, leads to the use of more varied antibiotics, causing a dangerous downward spiral . All the while antibiotics are entering the food chain and turning up in the human metabolic system to unpredictable, deleterious effect. Promise quickly turns to peril for the farmer, for the consumer, and for the future of vital aquaculture.
Feed LP20® can reverse this tide…
The details of this new study show its dramatic impact. In summary, researchers fed test stocks a diet supplemented with heat-killed Lactobacillus plantarum , strain L-137, the active ingredient in Feed LP20® . Key to the high effectiveness of Feed LP20® is the heat-killing process. It fully utilizes the strain’s characteristics, an area where House Wellness Foods holds an unparalleled position of authority based upon years of peer-reviewed testing and research, and continuous refinement of the development process. Heat treatment hardens bacillary cell walls and fixes their genetic material. Not only does this enable HK-L137 to resist initial breakdown in the upper gastric system, but it can be cooked, processed, stored, and administered in an aquatic environment without compromising potency. Further, both its ability to stimulate immune cytokine interleukin 12 and its shelf life far surpass that of any living lactobacillus supplement.
House Wellness Foods and the introduction of immunobiotics
Immunobiotics promote health by triggering immune responses in the mucosa. House Wellness Foods , one of Japan’s most trusted names in food production, began its exploration of immunobiotics and their ability to bolster human immune response, support liver function, and ameliorate the causes of chronic disease over three decades ago, and the culmination of their intensive research and meticulous development was their flagship Immuno-LP20® , with its active component of 20% heat-treated Lactobacillus plantarum L-137 (HK-L137). This potent lactobacillus follows a dual course on assimilation. It initiates production of signal molecule IL-12 and IFN-β cells — the latter being the most important single cytokine responsible for inhibiting viral multiplication; and it subsequently stimulates T cell activity and the production of both NK and cytotoxic T (CTL) effector cells, boosting innate immunity and fostering antibody creation as an adjunct to the adaptive immune response.
House followed the worldwide success of Immuno-LP20® , with the development of Feed LP20® , an alternative to antibiotics, and to the costly, unreliable, and lengthy process of cultivating disease-resistant strains of livestock. The overarching principle of immunobiotic therapy in both land-based and aquatic livestock is that the power to fight disease already exists within every living cell of the organism. Prior to the present study, Feed LP20® proved its remarkable effectiveness in other aquatic stock, including white leg shrimp and Nile tilapia . It recently began marketing in the EU as a complementary feed for poultry, swine, and salmonid.
The proof is in the food chain
The study shows that juvenile striped catfish fed HK-L137-supplemented diets exhibited higher final weight and specific growth rate than controlled stock given ordinary feed. The fish showed higher survival rate, longer life, better feed conversion ratios, weight gain, better protein efficiency ratios, and increased reproductive capacity. Further, a test sub-group was administered a bacterial challenge mirroring a real-life scenario in Vietnamese river farms of their most devastating bacterial threat, Bacillary Necrosis Disease (BNP), caused by the bacterial agent Edwardsiella ictaluri . Part of the test group was injected with this agent, and in every case the cumulative mortality of HK L-137-supplemented groups was lower than the group fed control diet.
Fitter fish, more successful farming, greater financial stability — all of this originating from the power of Feed LP20® , comprising 20% HK-L137 , to sustain health through enhanced immunity at the very cellular level. The new study shows the promise of House Wellness Foods’ Breakthrough Feed LP20®, and points to the future of a shared world that is often fragile, yet always filled with hope.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210330005016/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
